RaySearch Laboratories AB (publ) Interim Report January 1

“Revenues from RayStation® increased with 29 percent to SEK 80.8 M (62.8) and
prospects are favorable for increased growth for the rest of the year. The
development of RayCare® is progressing according to plan and we are planning a
public demonstration of the system at the 2016 ASTRO Annual Meeting in Boston at
the end of September,” says Johan Löf, President and CEO of RaySearch.
THREE MONTHS (JANUARY-MARCH 2016)

  · Net sales SEK 95.4 M (87.7), of which RayStation SEK 80.8 M (62.7)
  · Profit after tax SEK 17.8 M (25.0), and earnings per share SEK 0.52 (0.73)
  · Operating profit SEK 23.4 M (33.1)
  · Cash flow negative SEK 5.2 M (pos: 7.8)
  · Order intake excluding service agreements SEK 81.9 M (86.3), of which
RayStation SEK 72.6 M (69.1)
  · Order backlog for RayStation was SEK 47.1 M (34.3) at the end of the period

SIGNIFICANT EVENTS DURING THE FIRST QUARTER

  · RaySearch released RayStation 5 with support for carbon ion treatment
planning, as well as tools and features that represent a totally new approach to
treatment planning.
  · RaySearch signed a long-term collaboration agreement with the University of
California, San Francisco (UCSF) regarding RayCare.
  · On January 4, 2016, the Class B RaySearch share (RAY B) was transferred from
the Small to the Mid Cap segment of Nasdaq Stockholm.
  · In March 2016, 750 Class A shares were converted to Class B shares at the
request of a shareholder.

NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

ABOUT RAYSEARCH

RaySearch Laboratories AB (publ) is a medical technology company that develops
advanced software solutions for improved radiation therapy of cancer. RaySearch
markets the RayStation treatment planning system to clinics all over the world.
In addition, RaySearch’s products are distributed through licensing agreements
with leading medical technology companies. RaySearch’s software is used by over
2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin
-off from Karolinska Institute in Stockholm, and the company is listed in the
Mid Cap segment on Nasdaq Stockholm.

More information about RaySearch is available at www.raysearchlabs.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO
Tel: +46 8 510 530 00
johan.lof@raysearchlabs.com
RaySearch Laboratories AB (publ) Interim Report January 1 – March 31, 2016

Attachments
